HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 90/1/27    most recent expphysiol.2004.028126v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Baker, A. H. Articles by Nicklin, S. A. Search for Related Content PubMed PubMed Citation Articles by Baker, A. H. Articles by Nicklin, S. A. Related Collections Symposia Papers

¹ British Heart Foundation Cardiovascular Research Centre, Division of Cardiovascular and Medical Sciences, University of Glasgow, Church Street, Glasgow G11 6NT, UK

Abstract

Clinical gene therapy for cardiovascular disease remains achievable. To date, however, preclinical studies and clinical trials have highlighted shortfalls in viral gene delivery to vascular cells. These include poor efficiency, poor target tissue selectivity, the presence of pre-existing neutralizing antibodies and immunogenicity generated by the host to vectors such as adenovirus. These important issues require careful consideration when applying viral vectors for gene therapy. Each delivery vector requires precise optimization and tailoring for each disease application since parameters relating to vector : tissue exposure time, route of delivery and target cell type vary considerably. Optimization can be achieved through modification of the structure of the virus capsid proteins and expression cassette to generate vectors that are highly selective and efficient for target cell binding and entry as well as instilling transcriptional control and/or longevity on transgene expression. This ultimately will improve the efficacy and toxicity profiles of gene delivery vectors and has become a very important area in gene therapy. Here, we review recent advances in the targeting of viral gene delivery vectors to the vasculature.

(Received 19 August 2004; accepted after revision 15 October 2004; first published online 12 November 2004)
Corresponding author Andrew H. Baker, British Heart Foundation Cardiovascular Research Centre, Division of Cardiovascular and Medical Sciences, University of Glasgow, Church Street, Glasgow G11 6NT, UK. Email: ab11f{at}clinmed.gla.ac.uk

This article has been cited by other articles:

				A. R. Makela, H. Matilainen, D. J. White, E. Ruoslahti, and C. Oker-Blom Enhanced baculovirus-mediated transduction of human cancer cells by tumor-homing peptides. J. Virol., July 1, 2006; 80(13): 6603 - 6611. [Abstract] [Full Text] [PDF]

				G Murphy and M H Lee What are the roles of metalloproteinases in cartilage and bone damage? Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv44 - iv47. [Abstract] [Full Text] [PDF]